Automated Electronic Alert Systems for Acute Kidney Injury: Current Status and Future Perspectives

2016 ◽  
pp. 124-129 ◽  
Author(s):  
Eiichiro Uchino ◽  
Naoya Kondo ◽  
Takeshi Matsubara ◽  
Motoko Yanagita
Keyword(s):  
Acute Kidney Injury ◽  
Kidney Injury ◽  
Current Status ◽  
Future Perspectives

scholarly journals Proteomics in acute kidney injury—current status and future promise

2013 ◽  
Vol 29 (2) ◽  
pp. 163-171 ◽  
Author(s):  
Julie Ho ◽  
Allison Dart ◽  
Claudio Rigatto
Keyword(s):  
Acute Kidney Injury ◽  
Kidney Injury ◽  
Current Status

Mitochondria-targeted therapies for acute kidney injury

2014 ◽  
Vol 16 ◽  
Author(s):  
Luis Carlos Tábara ◽  
Jonay Poveda ◽  
Catalina Martin-Cleary ◽  
Rafael Selgas ◽  
Alberto Ortiz ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Mitochondrial Permeability Transition ◽  
Kidney Injury ◽  
Permeability Transition Pore ◽  
Permeability Transition ◽  
Transluminal Angioplasty ◽  
Experimental Models ◽  
Current Status ◽  
Ischaemia Reperfusion Injury ◽  
Tubular Cells

Acute kidney injury (AKI) is a serious clinical condition with no effective treatment. Tubular cells are key targets in AKI. Tubular cells and, specifically, proximal tubular cells are extremely rich in mitochondria and mitochondrial changes had long been known to be a feature of AKI. However, only recent advances in understanding the molecules involved in mitochondria biogenesis and dynamics and the availability of mitochondria-targeted drugs has allowed the exploration of the specific role of mitochondria in AKI. We now review the morphological and functional mitochondrial changes during AKI, as well as changes in the expression of mitochondrial genes and proteins. Finally, we summarise the current status of novel therapeutic strategies specifically targeting mitochondria such as mitochondrial permeability transition pore (MPTP) opening inhibitors (cyclosporine A (CsA)), quinone analogues (MitoQ, SkQ1 and SkQR1), superoxide dismutase (SOD) mimetics (Mito-CP), Szeto-Schiller (SS) peptides (Bendavia) and mitochondrial division inhibitors (mdivi-1). MitoQ, SkQ1, SkQR1, Mito-CP, Bendavia and mdivi-1 have improved the course of diverse experimental models of AKI. Evidence for a beneficial effect of CsA on human cardiac ischaemia–reperfusion injury derives from a clinical trial; however, CsA is nephrotoxic. MitoQ and Bendavia have been shown to be safe for humans. Ongoing clinical trials are testing the efficacy of Bendavia in AKI prevention following renal artery percutaneous transluminal angioplasty.

scholarly journals Practice of Extracorporeal Therapies for Septic Acute Kidney Injury Patients in Intensive Care Units in Mainland China

2019 ◽  
Vol 47 (Suppl. 3) ◽  
pp. 23-28
Author(s):  
Yu Zhou ◽  
Fachun Zhou ◽  
Xue Wang ◽  
Ping Chang ◽  
Ling Zhang ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Intensive Care ◽  
Clinical Practice ◽  
Mainland China ◽  
Kidney Injury ◽  
Current Status ◽  
Major Objective ◽  
Septic Acute Kidney Injury ◽  
Extracorporeal Therapy ◽  
Icu Physicians

Background: Continuous renal replacement therapy (CRRT) and other extracorporeal therapies for acute kidney injury (AKI) and other organ dysfunction syndromes in critically ill patients are common in the intensive care unit (ICU). Many studies have focused on clinical practice for managing these conditions. However, there are few studies that describe the utilization of extracorporeal therapies, especially CRRT, in patients with sepsis-associated AKI. Summary: Two hundred ICU physicians were included in a survey from February 28, 2017, to March 20, 2017, on the current status of septic AKI and clinical practice in CRRT. According to the responses, 40% of sepsis patients in the ICU had AKI, and 25% required extracorporeal therapies. However, 29% of candidates gave up therapy for medical or nonmedical reasons. Overall survival for sepsis was 60%; among survivors, 80% were dialysis free at discharge. CRRT was the most common modality of extracorporeal therapy in the ICU, and 82% of physicians chose convection as the major clearance mode. The survey showed 30% of physicians saw the removal of inflammatory mediators as the major objective of extracorporeal therapies; however, only 18.5% of physicians considered inflammation as a measure to trigger CRRT. The median treatment duration of CRRT in China was 12 h per day for 5 days. Key Messages: There were some similarities and differences in CRRT practice for septic AKI patients in China and globally. The differences reveal some insights into improving the outcomes of these patients.

scholarly journals Fibroblast Growth Factor 23 and αKlotho in Acute Kidney Injury: Current Status in Diagnostic and Therapeutic Applications

Nephron ◽  
2020 ◽  
Vol 144 (12) ◽  
pp. 665-672
Author(s):  
Javier A. Neyra ◽  
Ming Chang Hu ◽  
Orson W. Moe
Keyword(s):  
Acute Kidney Injury ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 23 ◽  
Kidney Injury ◽  
Current Status ◽  
Fibroblast Growth ◽  
Diverse Range ◽  
Association Data ◽  
Fgf 23

Fibroblast growth factor (FGF) 23 and αKlotho are circulating mineral regulatory substances that also have a very diverse range of actions. Acute kidney injury (AKI) is a state of high FGF23 and low αKlotho. Clinical association data for FGF23 are strong, but the basic pathobiology of FGF23 in AKI is rather sparse. Conversely, preclinical data supporting a pathogenic role of αKlotho in AKI are strong, but the human data are still being generated. This pair of substances can potentially serve as diagnostic and prognostic biomarkers. FGF23 blockade and αKlotho restoration can have prophylactic and therapeutic utility in AKI. The literature to date is briefly reviewed in this article.

scholarly journals Predicting acute kidney injury: current status and future challenges

2017 ◽  
Vol 31 (2) ◽  
pp. 209-223 ◽  
Author(s):  
Simona Pozzoli ◽  
Marco Simonini ◽  
Paolo Manunta
Keyword(s):  
Acute Kidney Injury ◽  
Kidney Injury ◽  
Current Status ◽  
Future Challenges
Sign in / Sign up

Export Citation Format

Share Document